Browsing by Author "Tsavaris, N."
Now showing items 1-8 of 8
-
Article
Combination chemotherapy with cisplatin and/or doxorubicin in malignant mesothelioma. A prospective study
Tsavaris, N.; Primikirios, N.; Mylonakis, N.; Varouchakis, G.; Dosios, T.; Pavlidis, Nicholas; Skarlos, Dimosthenis V.; Tasopoulos, T.; Dritsas, J.; Kosmidis, Paraskevas A. (1997)From June 1984 to October 1995, forty seven consecutive patients (pts) with a confirmed diagnosis of diffuse malignant mesothelioma (MM) of the pleura (41) and peritoneum (6), were treated with cisplatin (CDDP) (24 pts) ...
-
Article
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma
Tsavaris, N.; Mylonakis, N.; Karvounis, N.; Bacoyiannis, Charalambos; Briassoulis, E. Ch; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Stamatelos, G.; Kosmidis, Paraskevas A. (1994)From June 1985 to March 1993, 20 consecutive patients with histologically proven malignant mesothelioma were treated with cisplatin 100 mg/m2 i.v. infusion on day 1 and vinblastine 6 mg/m2 i.v. on day 1 and 8. Treatment ...
-
Article
Combination regimen with carboplatin, epirubicin and etoposide in metastatic carcinomas of unknown primary site: A Hellenic Co-operative Oncology Group phase II study
Briassoulis, E. Ch; Tsavaris, N.; Fountzilas, George; Athanasiades, A.; Kosmidis, Paraskevas A.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Samantas, E.; Pavlidis, Nicholas (1998)The encouraging results that have been reported for cisplatin combination chemotherapy in a minority of patients with cancer of unknown primary (CUP) together with the previously shown equal activity of carboplatin in this ...
-
Article
Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients
Fountzilas, George; Polichronis, A.; Katsohis, C.; Gennatas, Constantinos; Toussis, D.; Skarlos, Dimosthenis V.; Kosmidis, Paraskevas A.; Vassilaros, S.; Semoglou, C.; Giannakakis, T.; Fahantidis, E.; Klouvas, G. D.; Tsavaris, N.; Konstantaras, C.; Makrantonakis, P.; Kolotas, C.; Zamboglou, N.; Tsiliakos, S.; Hainoglou, D.; Mylonakis, N.; Pavlidis, Nicholas (1996)362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 ...
-
Article
Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: Analysis of a prospective randomized phase III trial
Kosmidis, Paraskevas A.; Tsavaris, N.; Skarlos, Dimosthenis V.; Theocharis, D.; Samantas, E.; Pavlidis, Nicholas; Briassoulis, E. Ch; Fountzilas, George (1996)Purpose: To investigate if double modulation of fluorouracil (5-FU) with leucovorin (folinic acid [FA]) and interferon alfa-2b (IFN 2b) improves responses and survival in comparison to single modulation of 5-FU with FA. ...
-
Article
High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer. A Hellenic Co-operative Oncology Group study
Fountzilas, George; Skarlos, Dimosthenis V.; Pavlidis, Nicholas; Makrantonakis, P.; Tsavaris, N.; Kalogera-Fountzila, Anna; Giannakakis, T.; Beer, M.; Kosmidis, Paraskevas A. (1991)Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the ...
-
Article
Megestrol acetate in cancer patients with anorexia and weight loss a hellenic co-operative oncology group (heCOG) study
Skarlos, Dimosthenis V.; Fountzilas, George; Pavlidis, Nicholas; Beer, M.; Makrantonakis, P.; Aravantinos, Gerasimos; Pantelakos, P.; Tsavaris, N.; Karpasitis, N.; Kosmidis, Paraskevas A. (1993)Fifty-two patients with hormone-independent cancer, who complained of anorexia and of weight loss with at least 10% received megestrol acetate (MA), 480 mg daily, during 1-21 weeks. of the 41 patients treated during 4 weeks ...
-
Article
Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma
Bafaloukos, Dimitrios; Pavlidis, Nicholas; Fountzilas, George; Skarlos, Dimosthenis V.; Klouvas, G. D.; Makrantonakis, P.; Giannakakis, T.; Tsavaris, N.; Kosmidis, Paraskevas A. (1996)Thirty-four patients with advanced malignant melanoma were treated with recombinant alpha-interferon (IFN) and chemotherapy consisting of carboplatin, vinblastine, and bleomycin (CVB). CVB was given for four cycles and IFN ...